NeoGenomics anticipates preliminary unaudited fourth quarter 2025 revenue of approximately $190 million and full-year 2025 revenue of $727 million.
The company announced a transition of the Chief Financial Officer.
CEO Tony Zook highlighted the commitment to providing cancer testing services to pathologists and oncologists in the community setting.
Revenue Growth
Year-over-year revenue growth of 11% expected for Q4 2025 and 10% for full-year 2025.
Chief Financial Officer Transition
Abhishek Jain will become the CFO on March 2, 2026, succeeding Jeff Sherman who will retire.
Broad Oncology Test Menus
NeoGenomics offers a wide range of oncology tests including innovations in therapy selection and monitoring.
- The preliminary revenue figures showcase NeoGenomics' position as a leading oncology diagnostic solutions provider.
- The CFO transition signifies a strategic move towards financial leadership aimed at scaling the organization in advanced cancer testing markets.
The announcement reflects NeoGenomics' growth trajectory and commitment to improving cancer patient outcomes.